MACKENZIE QUIGLEY: Open Payments
NPI 1144851486 · NEW ALBANY, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$444 in 17 payments from 13 companies in 2025. Trend: 2023 $0 · 2024 $87 · 2025 $444
Food & beverage: $444
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 1 | $131 |
| RECORDATI_RARE_DISEASES_INC. | 3 | $59 |
| Ascendis Pharma Endocrinology Inc | 2 | $37 |
| Amgen Inc. | 2 | $35 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $25 |
| ABBVIE INC. | 1 | $23 |
| Alexion Pharmaceuticals, Inc. | 1 | $22 |
| Soleno Therapeutics, Inc. | 1 | $22 |
| Insulet Corporation | 1 | $21 |
| Lilly USA, LLC | 1 | $19 |
Products named: CRENESSITY, ISTURISA, Yorvipath, TEPEZZA, JARDIANCE, STRENSIQ, VYKAT XR, Omnipod.
Industry payments across IN — which companies pay providers there.
